Technical CommentsCancer

Response to Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia”

See allHide authors and affiliations

Science Translational Medicine  17 Jul 2019:
Vol. 11, Issue 501, eaav0819
DOI: 10.1126/scitranslmed.aav0819

Article Information

vol. 11 no. 501

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication August 12, 2018
  • Accepted for publication June 18, 2019
  • .

Author Information

  1. Damian Lai1,2,
  2. Min Chen1,
  3. Jiechuang Su1,3,
  4. Xiaohu Liu1,2,
  5. Katharina Rothe1,3,
  6. Kaiji Hu1,
  7. Donna L. Forrest2,4,
  8. Connie J. Eaves1,2,3,
  9. Gregg B. Morin3,5 and
  10. Xiaoyan Jiang1,2,3,*
  1. 1Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
  2. 2Department of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  3. 3Department of Medical Genetics, University of British Columbia, Vancouver, BC V6H 3N1, Canada.
  4. 4Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  5. 5Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
  1. *Corresponding author. Email: xjiang{at}bccrc.ca

Altmetric

Article usage

Article usage: July 2019 to October 2020

AbstractFullPdf
Jul 20192422348243
Aug 2019349547
Sep 2019155523
Oct 2019184324
Nov 2019204417
Dec 2019203916
Jan 2020274314
Feb 2020204622
Mar 2020224025
Apr 2020182917
May 2020113315
Jun 2020113111
Jul 20208171
Aug 202014155
Sep 202062221
Oct 2020121913

Stay Connected to Science Translational Medicine

Navigate This Article